The continual presence of C3d but not IgG glomerular capillary deposition in stage I idiopathic membranous nephropathy in patients receiving corticosteroid treatment

Rui Zhang1,2, Zhi-yong Zheng1*, Jian-song Lin1, Li-juan Qu1 and Feng Zheng3

Abstract

Background: Pathologic diagnosis of stage I idiopathic membranous nephropathy (MN-I) requires electron microscopy or immunohistochemistry that shows a glomerular capillary staining pattern of IgG and C3. However, it is not uncommon that renal biopsy did not obtain sufficient material for electron microscopy and that IgG and C3 staining in glomeruli largely lost at biopsy due to corticosteroid treatment. Since C3d is one of the final degradation products of C3 that is more stable in vivo, we determine if C3d staining could be used as a novel immunohistochemical marker for MN-I.

Methods and results: 74 MN-I patients with electron microscopy proven MN-I were examined by immunoperoxidase staining of C3d. Intensive C3d staining was present in glomerular capillary like the staining pattern of IgG and C3 in MN-I. Importantly, in 40 MN-I patients who underwent corticosteroid treatment at biopsy the intensity and glomerular capillary pattern of C3d staining remained largely intact while the staining for IgG had substantially reduced and the pattern of glomerular capillary staining became unrecognizable.

Conclusions: C3d glomerular capillary staining may be a novel marker for pathologic diagnosis of MN-I that is continuously present at biopsy in patient who has received corticosteroid treatment.

Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/2120780075734479

Keywords: C3d, Membranous Nephropathy, Immune deposit
the formation of C3c and the final product C3d. Immunostaining of C3d has been widely applied to renal and liver transplant biopsies to help for acute rejection diagnosis [1-4]. An increase in C3d mesangial staining has also been reported in IgA nephropathy [5-7]. Additionally, there was a report of positive C3d staining in glomeruli of patients with MN [8]. Since our preliminary examination showed the presence of capillary C3d immunostaining like C3 and IgG in glomeruli of MN-I, we further examined if C3d could be used as an immune deposit marker for MN-I even after patients have been treated for a period with corticosteroid.

Methods
Case selection
Our department received 5110 renal biopsy specimens between June 2009 and July 2010 from 20 hospitals around China. The study was approved by the hospital’s Ethics and Research Committee. MN was diagnosed in 303 cases (5.9%) and 74 cases (24.4%) were MN-I. Among 74 MN-I, 40 patients have started corticosteroid therapy before biopsy (Group A) while 34 patients had not (Group B). 20 cases of mild mesangiproliferative glomerulonephritis (m-MsPGN) (Group C) and 10 cases of minimal change disease (MCD) were selected as controls for studying immunostaining pattern of C3d. Normal kidney sections were also examined.

Pathologic criteria
The renal biopsies were examined by optical microscopy, immunohistochemistry and electron microscopy. Sections for optical microscopy were stained with Haematoxylin and Eosin, Periodic acid-Schiff (PAS), Periodic acid-silver Methenamine and Masson’s Trichrom (PAM-Masson) stains. A minimal of eight glomeruli was required for pathological examination. The diagnosis of MN-I included minimal change in glomerular basement membranes under optical microscopy and IgG immunostaining showing a typical pattern of capillary staining and focal foot process effacement and focal subepithelial immune deposit under electron microscopy.

Immunohistochemistry
Immunostaining for C3d was performed using the EliVision™ system (Maixin. Biocompany, Fuzhou China). Briefly, deparaffinized sections were put in stainless steel pressure cooker with citrate buffer (pH 6.0) heating for antigen retrieval, following with 0.1% trypsin (Becton Dickinson and Company, USA) digestion for 90 s. Endogenous peroxidase activity was blocked with 3% hydrogen peroxide for 10 min. Tissues then were incubated with first antibody, rabbit polyclonal against C3d (ab15981, 1:1000, abcam, USA) for 2 h. After reacting with a polymer enhancer at 37°C for 20 min, tissues were incubated with a secondary antitbody, an anti-rabbit immunoglobulin conjugated with peroxidase-labeled dextran polymer (Maixin Biocompany, Fuzhou, China) 37°C for 30 min. Positive staining was revealed by immersing the sections in an aminoethyl carbazole substrate solution (ZSGB Biocompany, Fuzhou, China), followed by nuclear staining with hematoxylin [9].

In order to confirm the effect of using high-pressure heating and trypsin for antigen retrieval in C3d immunohistochemical staining, we chose serial sections of paraffin-embedded tissue of stage II idiopathic membranous nephropathy (MN-II) with no retrieval, either high-pressure heating or trypsin retrieval and high-pressure heating plus trypsin retrieval, respectively. Negative control was set in each group and primary antibody was replaced by phosphate-buffered saline (PBS).

Since C3c is another degradation product of C3b, we also performed immunostaining for C3c to compare with C3d for staining pattern and their presence after corticosteroid treatment. Immunostaining for IgG, IgM, IgA, and C1q were also performed. A semiquantitative measurement of the staining area was performed. A score of 0 to 3 was defined as: 0, no staining (negative); 1, < 25% of glomerulus stained (+, weak); 2, 25% to 50% glomerulus stained (+++, moderate); 3, >50% glomerulus stained (++++, strong) [4,10,11].

Statistical analysis
Values are expressed as mean ± SD. Results were analyzed by nonparametric test, chi-square test and Fisher’s exact probability test using SPSS 16.0 software. A P value of less than 0.05 was considered statistical significance.

Results
Characteristics of patients and renal pathology
Demographic profile such as age and sex and clinical presentations such as proteinuria were similar between MN-I patients treated without or with corticosteroid before biopsy (Table 1). Similar amount of proteinuria between treated and untreated patients suggests that corticosteroid treatment had not been effective at the time. Clinical features of m-MsPGN patients were also listed on Table 1. Histological findings for MN-I patients included slight dilatation of the glomerular capillary lumens with basement membranes showing slightly stiffness but normal thickness. Podocytes appeared swollen. Under transmission electron microscope, there were sparse, minute, subepithelial deposits. Focal foot process effacement could be seen (data not shown).

C3d
Deposition of C3d in glomeruli was examined by immunoperoxidase staining. C3d staining was essentially negative in normal kidney glomeruli (data not shown). A
strong C3d staining was universally present in glomeruli of MN-I patients who have not received corticosteroid therapy at biopsy (Figure 1A). The staining in MN-I glomeruli showed a predominantly capillary pattern like the pattern of IgG staining (Figure 1B). Immunostaining for C3c, another degradation product of C3b, showed similar capillary pattern like C3d in MN-I but was with much lesser intensity (Figure 1C).

We further evaluated the presence and pattern of C3d staining in glomeruli of MCD and m-MsPGN. C3d staining was seen in part of mesangium in MCD (Figure 2A). The mesangial staining was more obvious in m-MsPGN and the staining occasionally was extended to glomerular capillary (Figure 2B). Nevertheless, the staining pattern of C3d in both MCD and m-MsPGN was mostly mesangium dominant and was clearly different from capillary pattern found in MN-I (Figure 2C).

It is known that glomerular staining of IgG and C3 in MN-I would largely reduce and the pattern of capillary staining became either unrecognizable or largely lost after corticosteroid therapy. To determine if this would also be the case for C3d, we compared the intensity and staining pattern of C3d in biopsy samples from patients treated with and without corticosteroid, and also compared the incidence of C3d, C3c and IgG staining. As expected, the staining for glomerular IgG in MN-I was substantially reduced and capillary pattern of staining had largely lost after corticosteroid treatment (Figure 3D). C3c staining was disappeared (Figure 3E). On the contrary, C3d staining remained as strong and glomerular capillary staining

### Table 1 Clinic characteristics of the three groups of patients

|                      | Group A (n = 40) | Group B (n = 34) | Group C (n = 20) |
|----------------------|------------------|------------------|------------------|
| Sex (male/female)    | 20/20            | 17/17            | 12/8             |
| Age (years)          | 45.50 ± 14.82    | 46.79 ± 13.62    | 24.95 ± 14.10    |
| Time to biopsy (days)| 113.90 ± 105.46  | 55.03 ± 63.67    | 59.85 ± 78.60    |
| Steroid treatment (%)| 100              | 0                | 65               |
| MAP (mmHg)           | 94.45 ± 10.00    | 92.78 ± 10.81    | 88.42 ± 10.23    |
| Hematuria (%)        | 0                | 0                | 5                |
| Proteinuria (g/24 h) | 5.80 ± 3.15      | 4.21 ± 2.37      | 3.72 ± 3.47      |
| SCr (umol/L)         | 74.89 ± 26.42    | 59.34 ± 13.03    | 77.01 ± 37.94    |
| BUN (mmol/L)         | 5.27 ± 1.59      | 3.89 ± 1.06      | 5.37 ± 1.88      |

Group A: patients treated with corticosteroid before biopsy.
Group B: patients treated without corticosteroid before biopsy.
Group C: patients with mild mesangioproliferative glomerulonephritis.

Figure 1 Glomerular C3d, IgG and C3c staining in MN-I. **A**, A strong C3d staining was universally present in glomerular capillary. **B**, The IgG staining in glomeruli showed a predominantly capillary pattern. **C**, Staining for C3c showing similar capillary pattern but much lesser intensity.
pattern was unchanged in MN-I patients treated with corticosteroid (Figure 3F). Figure 3A, Figure 3B and Figure 3C showed IgG, C3c and C3d staining in biopsy samples from patients treated without corticosteroid, respectively. As shown in Table 2, group A showed a significantly higher incidence of C3d and the intensity of C3d was also significantly stronger than that of IgG and C3c ($P < 0.01$). Moreover, the incidence of IgG and C3c were significantly higher in group B than group A, the intensity of IgG and C3c were significantly stronger in group B, compared to group A ($P < 0.01$). However, no differences for intensity and incidence of C3d were found between group A and group B.

**Antigen retrieval effect**
Cases of MN-II with high-pressure heating plus trypsin retrieval, C3d staining was strongly positive in capillary loop, no backgroud (Figure 4B). With no antigen retrieval, C3d staining was faintly positive (Figure 4D). With trypsin retrieval, C3d staining was weakly positive.
(Figure 4F). With high-pressure heating retrieval, C3d was moderately positive (Figure 4H), and Controls were negative (Figure 4C, 4E, 4G and 4I). Figure 4A showed the PAM-Masson stain study.

Discussion
Due to its minor change under optical microscopy, the diagnosis of MN-I depends largely on electron microscopy. However, some biopsy materials may not be sufficient for electron microscope examination. For instance, we received 5110 renal biopsy specimens from hospitals all over the China between June 2009 and July 2010, of which 1328 cases (26.0%) did not have sufficient tissue for electron microscopy. Immune complex formation in subepithelial and resultant complement activation has been implicated in the pathogenesis of MN. A typical glomerular capillary pattern of IgG and C3 depositions is present in patients with MN. Since IgG and C3 staining are largely negative in MCD and show predominantly a pattern of mesangial staining in m-MsPGN, two diseases with minimal changes under optical microscopy like MN-I, IgG and C3 immunostaining are very helpful for differential diagnosis amongst MN-I, MCD and m-MsPGN when electron microscopy is missing. However, the staining intensity and pattern of IgG and C3 are significantly affected by corticosteroid treatment. In this study, we found an exclusively positive and strong glomerular capillary IgG staining in biopsy samples obtained from MN-I patients untreated with corticosteroid. In biopsy samples obtained from MN-I patients have been treated with corticosteroid, however, only 52.5% of tissues showed a weak IgG glomerular staining and the capillary staining pattern became largely unrecognizable in most of patients.

C3b is one of the cleavage products of C3 that plays a critical role in activating both classical and alternative pathways of complement. C3b is degraded stepwise to inactive C3b and then to C3c and C3dg. C3d is a final cleavage product of C3dg and is a stable marker of complement activation that binds covalently to cell surfaces and basement membrane, so it can persist for a long time in the tissue. C3d deposition has been found in patients with MN [7]. We examined glomerular staining of both C3c and C3d in MN-I patients. Although both C3c and C3d are final degradation products of C3b, the intensity of C3c glomerular staining was substantially weaker than C3d. This may be due to the problem of anti-C3c antibody or a shorter half-life of C3c [12,13].

Table 2 The results of immunohistochemistry examination in group A and group B

| Positive part | IgG       | IgM | IgA       | C3c          | C3d          | C1q          |
|--------------|-----------|-----|-----------|--------------|--------------|--------------|
| Group A (n = 40) capillary lumens | 0.95 ± 1.11 (52.5%) | 0 | 0 | 0.03 ± 0.16 (3.33%) | 3.00 ± 0.00 (100%) | a 0 |
| Group B (n = 34) capillary lumens | 2.94 ± 0.24 (100%) | 0 | 0 | 0.29 ± 0.58 (23.5%) | 3.00 ± 0.00 (100%) | 0 |

Group A: patients treated with corticosteroid before biopsy. Group B: patients treated without corticosteroid before biopsy.

* P <0.01 versus IgG and C3c in the same group; b P <0.01 versus group A.
Nevertheless, C3c staining is also significantly affected by corticosteroid treatment. Both intensity and incidence of C3c glomerular staining was substantially reduced in MN-I patients treated with corticosteroid at biopsy. In contrast, C3d glomerular staining was strong and showed a typical capillary pattern in MN-I and remained largely unchanged by corticosteroid therapy. Additionally, we found that the completely sclerosing glomeruli showed C3d-positive (Figure 4B), which indicating that C3d could persist for a long time in the tissue and didn’t disappear. Since glomerular staining of C3d is either negative or shows a mesangial dominantly pattern in patients with MCD and m-MsPGN, C3d immunostaining could be applied as a good immune deposit marker for pathologic diagnosis of MN-I, especially in condition that patient has been treated with corticosteroid. Since corticosteroid treatment seemed largely ineffective judged by the present of intensive proteinuria in MN-I patients included in this study, it is unclear if C3d staining would remain in patients after successful corticosteroid treatment. Additionally, the molecular basis of different intensity and pattern of C3c and C3d glomerular staining in MN-I patients is unknown.

The C3d staining results of comparison showed that the use of high-pressure heating and trypsin for antigen retrieval can get the best staining results. With no antigen retrieval C3d staining was faintly positive. With trypsin retrieval C3d staining was weakly positive. With high-pressure heating retrieval C3d staining was moderately positive. Controls showed negative. These results suggested that antigen retrieval twice can improve the renal biopsy paraffin-embedded tissues by immunochemical method and does not cause false positive and background staining.

Conclusions
In summary, our study suggests that C3d glomerular capillary staining may be a novel marker for pathologic diagnosis of MN-I that is continuously present at biopsy in patient who has received corticosteroid treatment. This finding is particularly significant when there are no sufficient biopsy materials to process for electron microscopy which is considered to be the gold standard for the diagnosis of MN.

Abbreviations
MAP: Media arterial pressure; SC: Serum creatinine; BUN: Blood urea nitrogen; MN: Membranous nephropathy; MN-I: Stage I idiopathic membranous nephropathy; MN-II: Stage II idiopathic membranous nephropathy; m-MsPGN: Mild mesangioproliferative glomerulonephritis; MCD: Minimal change disease; PBS: Phosphate-buffered saline.

Competing interest
The authors declare that they have no competing interests.

Authors’ contribution
RZ and ZZ designed the study, performed research and wrote the first draft of the manuscript, JL and LQ participated in its research and the sequence alignment. FZ helped to draft the final version of the manuscript. All authors read and approved the final manuscript.

Acknowledgments
We thank all colleagues who recorded medical information, collected the clinical data, performed renal biopsies and provided immunohistochemical staining technique assistance for our studies. This study was supported by the Nanjing Military Fuzhou General Hospital Research Fund 201046 and Nanjing Military Medicine & Health Division Fund 08MA103.

Author details
1Department of Pathology, Dongfang Hospital, Fujian Medical University, Fuzhou 350025, China. 2Department of Pathology, The Second hospital of Xiamen, Xiamen 361021, China. 3Department of Nephrology, Dongfang Hospital, Fujian Medical University, Fuzhou 350025, China.

Received: 20 May 2012 Accepted: 12 August 2012 Published: 21 August 2012

References
1. Gerej B, Górecka B, Wasiyutyski A: Role of C3d and C4d complement fragments in the diagnostics of acute allograft rejection after transplantations. Ann Transplant 2009, 14:61–70.
2. Herman J, Lerut E, Van Damme-Lombaerts R, Emonds MP, Van Damme B: Capillary deposition of complement C4d and C3d in pediatric renal allograft biopsies. Transplantation 2005, 79:1435–1440.
3. Haas M, Rahman MH, Racusen LC, Kraus ES, Bagnasco SM, Segev DL, Simpkins CE, Warren DS, King KE, Zachary AA, Montgomery RA: C4d and C3d staining in biopsies of ABO- and HLA-incompatible renal allografts: correlation with histologic findings. Am J Transplant 2006, 6:1829–1840.
4. Kuppers DR, Lerut E, Evenepoel P, Maes B, Vanrenterghem Y, Van Damme B: C3d deposition in peritubular capillaries indicates a variant of acute renal allograft rejection characterized by a worse clinical outcome. Transplantation 2003, 76:102–108.
5. Hakagawa H, Suzuki S, Haneda M, Geyko F, Kikawa R: Significance of glomerular deposition of C3c and C3d in IgA nephropathy. Am J Nephrol 2000, 20:122–128.
6. Gherghieanu M, Penescu M, Mandache E: The predictive value of peritubular capillaries C3d deposition in IgA golmerulonephritis. J Cell Mol Med 2005, 9:143–152.
7. Salling J: Circulating immune complexes and complement breakdown product C3d in glomerulonephritis and kidney transplantation. Acta Pathol Microbiol Scand C 1984, 92:213–220.
8. Dai T, Kanatsu S, Nagai H, Suhir F, Kawaiha T, Harashina Y: Demonstration of C3d deposits in membranous nephropathy, Nephron 1984, 37:232–235.
9. Ying-hao Y, Zhi-yong Z, Lin Z: The use of ELIsight™ system in renal biopsy specimens. J Clin Exp Pathol 2005, 21:819.
10. Braudtse E, Laurinacius A: Digital pathology evaluation of complement C4d component deposition in the kidney allograft biopsies is a useful tool to improve reproducibility of the scoring. Diagn Pathol 2011, 6(Suppl 1):S5.
11. Yan Q, Wang B, Sui W, Zou G, Chen H, Xie S, Zou H: Expression of GSK-3β in renal allograft tissue and its significance in pathogenesis of chronic allograft dysfunction. Diagno Pathol. 2012, 7:5.
12. Schulze M, Pruchno CJ, Burns M, Baker PJ, Johnson R1, Couser WG: Glomerular C3c localization indicates ongoing immune deposit formation and complement activation in experimental glomerulonephritis. Am J Pathol 1993, 142:179–187.
13. Kumada K, Suzuki J, Kume K, Suzuki S, Yoshida K, Isome M, Kato K, Suzuki H, Yuge E: Clinicopathological study of Henoch-Schönlein purpura nephritis with special reference to C3c deposits. Jpn J Nephrol. 1996, 38:259–268.

doi:10.1186/1746-1596-7-109

Cite this article as: Zhang et al.: The continual presence of C3d but not IgG glomerular capillary deposition in stage I idiopathic membranous nephropathy in patients receiving corticosteroid treatment. Diagnostic Pathology 2012 7:109.